<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902418</url>
  </required_header>
  <id_info>
    <org_study_id>1R01MH116771-01A1</org_study_id>
    <nct_id>NCT03902418</nct_id>
  </id_info>
  <brief_title>Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women</brief_title>
  <acronym>PrEP-PP</acronym>
  <official_title>Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct an observational cohort study in 1200 pregnant women who will&#xD;
      be recruited at the first antenatal care (ANC) visit from the Gugulethu and one additional&#xD;
      facility in the Klipfontein-Mitchell's Plain subdistrict of the Metro Region (to be&#xD;
      identified in conjunction with provincial and local health authorities) Midwife Obstetric&#xD;
      Units in Cape Town (n=600 pregnant women per site). The enrolled women will be followed&#xD;
      through 12-months post-delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to:&#xD;
&#xD;
      1. Determine the distribution of women across the PrEP cascade:&#xD;
&#xD;
        1. Evaluate the proportion of pregnant and breastfeeding women who initiate PrEP out of all&#xD;
           women offered PrEP&#xD;
&#xD;
        2. Evaluate the proportion of pregnant and breastfeeding women who are retained in the PrEP&#xD;
           cohort&#xD;
&#xD;
        3. Evaluate the proportion of pregnant and breastfeeding women who initiate PrEP who adhere&#xD;
           to PrEP using objective dried blood spot measures and subjective measures of&#xD;
           self-reported pill count and adherence&#xD;
&#xD;
        4. Evaluate the proportion of pregnant and breastfeeding women on PrEP (and not on PrEP)&#xD;
           who acquire HIV, who transmit HIV to their infant, and who report adverse events 2.&#xD;
           Evaluate patient and provider-level factors associated with the PrEP cascade using&#xD;
           quantitative and qualitative approaches (including in-depth interviews) 3. Apply an&#xD;
           established mathematical model to simulate the impact of improvement in the PrEP cascade&#xD;
           on HIV infections averted (maternal and perinatal)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants initiating pre-exposure prophylaxis during pregnancy</measure>
    <time_frame>Percentage of participants initiating pre-exposure prophylaxis between first ante-natal clinic visit and birth of infant</time_frame>
    <description>Percentage of participants initiating pre-exposure prophylaxis during pregnancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants missing pre-natal visit</measure>
    <time_frame>Percentage of participants missing one monthly pre-natal visit between first pre-natal visit and birth of infant</time_frame>
    <description>Percentage of participants missing one monthly pre-natal visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to TDF at 3rd trimester delivery</measure>
    <time_frame>Measured at delivery</time_frame>
    <description>Percentage of participants with red blood cells with &gt;80% levels at &gt;40ng/mL TDF-DP at 3rd trimester delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Women initiating pre-exposure prophylaxis post-partum</measure>
    <time_frame>Percentage of participants initiating pre-exposure prophylaxis at first post-partum to final post-partum visit 12 months after birth</time_frame>
    <description>Percentage of women initiating pre-exposure prophylaxis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to TDF at 6 months post-partum</measure>
    <time_frame>Measured at 6-month post-partum visit</time_frame>
    <description>Percentage of participants with red blood cells with &gt;80% levels at &gt;40ng/mL TDF-DP at 6 month post-partum visit</description>
  </primary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>HIV-I Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine/tenofovir</intervention_name>
    <description>Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired</description>
    <other_name>Behavioral Counseling</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study counselors will enroll consecutive eligible, consenting pregnant adolescent girls&#xD;
        (&gt;16 years) and women in ANC (n=600 women per site; N=1200 pregnant women) and follow them&#xD;
        up for 12-months postpartum or until censorship for a mean of 18-months' follow-up.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;16 years of age,&#xD;
&#xD;
          -  confirmed HIV-negative (using 2 rapid tests,&#xD;
&#xD;
          -  confirmed with a 4th generation antigen HIV test;&#xD;
&#xD;
          -  lives within 20 km. of the clinic;&#xD;
&#xD;
          -  confirmed to be pregnant;&#xD;
&#xD;
          -  without psychiatric or medical contraindications to PrEP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent enrollment in another HIV-1 vaccine or prevention trial;&#xD;
&#xD;
          -  medical hospitalization in the past year for any reason;&#xD;
&#xD;
          -  receipt of TB treatment in the past 30 days; history of renal disease;&#xD;
&#xD;
          -  exhibiting psychotic symptoms (including hallucinations, suicidal or homicidal&#xD;
             ideation, or violent behavior),&#xD;
&#xD;
          -  currently or history of taking anti-psychotic medications;&#xD;
&#xD;
          -  positive Hepatitis B surface antigen test on screening;&#xD;
&#xD;
          -  history of bone fracture not related to trauma;&#xD;
&#xD;
          -  any other medical, psychiatric, or social condition which in the opinion of the&#xD;
             investigators would affect the ability to consent and/or participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Landon Myer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>THOMAS J COATES, PhD</last_name>
    <phone>3103679044</phone>
    <email>tcoates@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dvora Joseph Davey, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dvora J Davey, PhD</last_name>
      <phone>+27829430587</phone>
      <email>dvoradavey@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Dvora Joseph Davey, PhD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prevention in Pregnant and Breastfeeding Women</keyword>
  <keyword>HIV Pre-Exposure Prophylaxis (PrEP)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

